Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial to Assess the Safety of Sublingual Formulation of Metoclopramide (NIC-001) and Compare the Pharmacokinetic Profile to the Oral Formulation of this Drug Available in Market

Next Previous
Trial Profile

A Phase II Clinical Trial to Assess the Safety of Sublingual Formulation of Metoclopramide (NIC-001) and Compare the Pharmacokinetic Profile to the Oral Formulation of this Drug Available in Market

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metoclopramide (Primary) ; Metoclopramide
  • Indications Gastroparesis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nanologica

Most Recent Events

  • 18 Nov 2020 According to a Nanologica media release, the start of this study has been further advanced due to COVID-19. The study is expected to start no earlier than after the summer of 2021.
  • 11 Feb 2020 According to a Nanologica media release, the company plans to conduct this study in Australia in 2020.
  • 16 Jan 2020 According to Nanologica media release, results of the study can be expected by the end of 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top